Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

BACKGROUND: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuri...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Nephrol
Autori principali: Bakris, George L., Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C., Schloemer, Patrick, Filippatos, Gerasimos
Natura: Artigo
Lingua:Inglês
Pubblicazione: S. Karger AG 2019
Soggetti:
Patient-Oriented, Translational Research: Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888890/
https://ncbi.nlm.nih.gov/pubmed/31655812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503713
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi